Scleroderma has no single cure, but a growing range of treatments can slow organ damage, ease symptoms, and meaningfully improve quality of life. Because the disease can affect the skin, lungs, blood vessels, kidneys, and digestive tract in different combinations and to different degrees, treatment is tailored organ by organ rather than delivered as a one-size-fits-all regimen. The 2024 British Society for Rheumatology guideline reflects this shift, recommending that doctors look beyond simple skin classification and instead factor in antibody profiles and specific organ involvement when planning care.
How Treatment Decisions Are Made
Scleroderma (systemic sclerosis) has traditionally been split into two main subtypes based on how much skin is affected: limited cutaneous, where thickening stays mostly on the hands, face, and lower arms, and diffuse cutaneous, where it spreads more widely and tends to involve internal organs earlier. While that distinction still matters, current guidelines stress that it is not enough on its own to guide treatment. Antibody type, organ involvement, and how quickly the disease is progressing all shape the plan.1Rheumatology. The 2024 British Society for Rheumatology guideline for management of systemic sclerosis
A French cohort study of over 1,600 patients found that classifying people by antibody status predicted organ complications and survival more reliably than skin extent alone. Determining the specific antibody type at diagnosis helped doctors anticipate which organs were most at risk and personalize monitoring accordingly.2RMD Open. Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc In practice, this means two people with identical-looking skin changes may receive very different treatment plans depending on their blood work and imaging results.
Immunosuppressive Drugs for Skin and Lung Disease
Two immunosuppressive medications form the backbone of treatment when scleroderma causes skin thickening or lung scarring (interstitial lung disease, or ILD): mycophenolate mofetil and cyclophosphamide. The landmark Scleroderma Lung Study II compared the two head-to-head and found that both produced meaningful improvements in lung function over two years.3The Lancet Respiratory Medicine. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II) Follow-up analyses showed that both drugs also significantly improved skin thickness scores in patients with diffuse disease, with no clear winner between them.4PubMed Central. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness
In everyday practice, mycophenolate has largely become the preferred first choice for most patients. It is taken as a daily pill rather than a monthly intravenous infusion, and its side-effect profile is generally more tolerable over the long haul. Cyclophosphamide tends to be reserved for more aggressive disease or situations where mycophenolate has not worked, partly because of concerns about bladder toxicity and infection risk with prolonged use.
Slowing Lung Scarring with Antifibrotic Therapy
Nintedanib, originally developed for a different type of lung scarring, has become an important addition for scleroderma-related ILD. A large randomized trial found that nintedanib cut the rate of lung function decline nearly in half compared to placebo: patients on the drug lost about 52 milliliters of lung capacity per year, versus about 93 milliliters in the placebo group.5PubMed. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease The benefit was particularly striking in patients who were not already taking mycophenolate, where the gap between nintedanib and placebo widened further.6The Lancet Respiratory Medicine. Efficacy and safety of nintedanib in subgroups by mycophenolate use
That finding raises a practical question many patients and their doctors face: should you use nintedanib alone, mycophenolate alone, or both? The subgroup data suggest combining them may offer added protection, since nintedanib still showed a trend toward benefit even in patients already on mycophenolate. Many scleroderma centers now use both together for patients with progressive ILD, though the combination does increase the chance of gastrointestinal side effects like diarrhea and nausea.
Blood Vessel Problems and How They Are Managed
Scleroderma can damage small and medium-sized blood vessels throughout the body. Two of the most troublesome vascular complications are pulmonary arterial hypertension (high blood pressure in the lung arteries) and digital ulcers (painful sores on the fingertips caused by poor blood flow).
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is one of the leading causes of death in scleroderma, so treating it aggressively matters. The current standard is upfront combination therapy with two drug classes rather than starting with one and adding a second only if the first fails. Clinical trials have shown that combining an endothelin receptor antagonist with a PDE5 inhibitor improves heart function, exercise capacity, and lowers the risk of the disease getting worse compared to using either drug alone.7Integrated Blood Pressure Control. Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis There is even preliminary evidence from a real-world case series suggesting that starting combination therapy early could help prevent PAH from developing in high-risk patients, though this needs much larger studies to confirm.8PubMed Central. Can Combination Therapy with Endothelin Receptor Antagonist and PDE5 Inhibitors Prevent Echocardiographic Findings Suspicious for Pulmonary Arterial Hypertension?
Digital Ulcers
Digital ulcers can be excruciatingly painful and sometimes lead to infection or tissue loss. No drug is specifically approved by the FDA for treating digital ulcers in scleroderma, but several approaches are used. Calcium channel blockers and prostacyclin analogs can improve blood flow to the fingers. Endothelin receptor antagonists, better known for PAH, have also shown benefit in preventing new ulcers from forming.9PubMed Central. Optimal management of digital ulcers in systemic sclerosis Keeping hands warm, protecting fingertips from trauma, and wound care are just as important as medication. For severe or non-healing ulcers, procedures to improve blood flow or surgical removal of dead tissue sometimes become necessary.
Kidney Crisis
Scleroderma renal crisis is one of the most dramatic emergencies in this disease. Blood pressure spikes suddenly, and kidney function can deteriorate within days. It happens more often in people with diffuse skin disease and, strikingly, is more common in patients who have been on corticosteroids, with the risk climbing as the steroid dose goes up.10PubMed. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis
ACE inhibitors transformed the prognosis of this complication. Before they were widely used, renal crisis was often fatal. Now, aggressive blood pressure control with ACE inhibitors, sometimes combined with other blood pressure drugs, can stabilize or even reverse kidney damage in many patients. This is one of the clearest success stories in scleroderma treatment, but it comes with an important caveat: unlike in most other diseases, ACE inhibitors are used to treat scleroderma renal crisis, not to prevent it. Starting them prophylactically in all scleroderma patients has not been shown to help and may actually mask the early warning signs of crisis. The key takeaway for patients is to watch for sudden blood pressure spikes and report them immediately.
Digestive Tract Involvement
The gastrointestinal tract is affected in the vast majority of people with scleroderma. The range of symptoms is wide: some people have mild acid reflux, while others develop severe problems with their esophagus, stomach, or intestines that can lead to difficulty swallowing, bloating, malabsorption, weight loss, and serious malnutrition.11PubMed Central. Management of gastrointestinal involvement in scleroderma
Treatment is symptom-driven. Proton pump inhibitors are the first line for reflux and esophageal inflammation. Prokinetic agents can help when the stomach or intestines move food too slowly. Bacterial overgrowth in the small intestine, which causes bloating and diarrhea, is treated with rotating courses of antibiotics. Nutritional support, including dietary counseling and sometimes supplemental tube feeding, becomes important when absorption is compromised. Because GI symptoms tend to be chronic and fluctuating, regular reassessment and adjustment are part of the long game.
Biologic Therapies Targeting Inflammation and Fibrosis
Newer biologic drugs are opening up options for patients who do not respond well to traditional immunosuppressants. The most studied include tocilizumab (which blocks the inflammatory signal IL-6), rituximab (which depletes a type of immune cell called B cells), and fresolimumab (which targets TGF-beta, a growth factor that drives scarring).12PubMed Central. Recent advances in the treatment of skin involvement in systemic sclerosis
Tocilizumab has shown some of the most encouraging early results. In a small study, two patients treated for six months experienced skin softening of roughly 50 percent as measured by both a device that tests skin hardness and by clinical skin scoring.13Rheumatology. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab Larger trials have since explored tocilizumab for skin and lung involvement, and while results have been mixed on some endpoints, the drug is increasingly used off-label at specialized centers for patients with progressive disease. Rituximab similarly appears in observational studies and small trials, often in patients whose skin or lungs are worsening despite mycophenolate.
Stem Cell Transplantation
For patients with rapidly progressing diffuse scleroderma, autologous hematopoietic stem cell transplantation (HSCT) is the most aggressive available therapy and, in the right patients, one of the most effective. The procedure essentially reboots the immune system: the patient’s own stem cells are collected, the existing immune system is wiped out with high-dose chemotherapy, and the stem cells are returned to rebuild it from scratch.14PubMed Central. Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis: Current Evidence and Future Directions
The SCOT trial, a landmark randomized study, found that transplant recipients had far better long-term outcomes than patients treated with monthly cyclophosphamide. At six years, overall survival was about 86 percent in the transplant group versus 51 percent with cyclophosphamide alone.15PubMed Central. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma Those numbers are striking, but they come with real risk. A meta-analysis pooling data from 700 patients across multiple studies found that about 6 percent of transplant recipients died from treatment-related complications, though the rate has been dropping as centers gain experience and refine patient selection.16Modern Rheumatology. Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis HSCT is reserved for younger patients with severe, progressive disease and relatively preserved organ function, and it is only performed at highly specialized centers.
Calcinosis
Calcium deposits under the skin are one of the most frustrating aspects of scleroderma for patients. These hard lumps can push through the skin surface, cause chronic pain, and become infected. Despite decades of research, no medication has proven reliably effective in large trials. A few small observational studies have reported modest benefit with minocycline (an antibiotic with anti-inflammatory properties) and with topical sodium thiosulfate applied directly to the deposits. When deposits are large, painful, or prone to infection, surgical removal remains the most effective option.17PubMed Central. Calcinosis in systemic sclerosis The lack of proven medical treatments for calcinosis is an active area of unmet need in scleroderma care.
Rehabilitation and Managing Pain and Fatigue
Tight, thickened skin on the hands can severely limit grip strength and finger movement. Exercise and physical therapy are recognized as important parts of treatment, but how that exercise is delivered matters. A recent study comparing physiotherapist-guided telerehabilitation with a self-directed home exercise program found that patients who had real-time guidance from a therapist over video showed greater improvements in hand mobility and grip strength than those exercising on their own.18PubMed. Which physiotherapy method is more effective for hand rehabilitation in patients with scleroderma For people who live far from a scleroderma center, telerehabilitation offers a practical way to get expert guidance without traveling.
Beyond the hands, pain and fatigue are pervasive complaints that often fly under the radar because they are harder to measure than lung function or skin thickness. A review of non-drug approaches found promising results from physical rehabilitation, cognitive behavioral therapy, nutritional support, and mind-body practices like meditation and yoga, although the authors noted that high-quality evidence in scleroderma specifically is still limited.19PubMed Central. Pain and fatigue in systemic sclerosis: Practical strategies for non-pharmacological management These interventions are not substitutes for medical therapy, but they address dimensions of the disease that pills alone do not reach.
Localized Scleroderma Is Treated Differently
Localized scleroderma (sometimes called morphea) affects only the skin and underlying tissue, without the internal organ involvement of systemic sclerosis. The treatment approach is different because the goals are different: controlling inflammation in the skin patches, preventing permanent damage to deeper structures, and minimizing cosmetic impact. Methotrexate is the most commonly used systemic treatment, while ultraviolet A light therapy is an alternative. A meta-analysis of studies in children found that both UVA phototherapy and methotrexate had favorable effects on active lesions.20PubMed. Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma
For cases that do not respond to these standard options, early case reports and small series suggest that JAK inhibitors, a class of drugs that tamps down immune signaling through a different pathway, may help. A systematic review found the early results promising but emphasized that the evidence is still limited to individual case reports and very small series. JAK inhibitors should be considered cautiously and only in patients who have failed conventional therapy.21PubMed Central. Janus kinase inhibitors in localized scleroderma: a systematic literature review
Treating Children and Adolescents
Juvenile systemic sclerosis is rare, and published treatment data in children consist mostly of case reports rather than controlled trials.22Rheumatology. Consensus-based recommendations for the management of juvenile systemic sclerosis In practice, treatment plans for children are often adapted from adult guidelines, but some important differences exist. An international expert consensus published in 2023 noted that the role of corticosteroids, for instance, may differ between children and adults, and that organ-specific management sometimes requires adjustments for a developing body.23PubMed. Best clinical practice in the treatment of juvenile systemic sclerosis Experts have called for the development of age-specific treatment guidelines, since children are not simply small adults and the disease can behave differently in younger patients. Families of affected children should ideally be managed at centers with pediatric rheumatology expertise.
How Treatment Response Is Measured
One challenge in scleroderma care is knowing whether treatment is actually working. Lung function can be tracked with breathing tests, and blood pressure and kidney function with routine labs. But for skin involvement, the main tool is the modified Rodnan skin score, a hands-on examination where a clinician pinches the skin at 17 body sites and rates the thickness at each one. It correlates well with skin biopsy findings and has been sensitive enough to pick up differences between active drugs and placebo in major clinical trials.24PubMed Central. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis For patients, this means that a visit to the rheumatologist typically includes this physical exam alongside imaging and blood work, and improvement in the skin score over time is one tangible way to tell if an immunosuppressive drug or biologic is helping.
The score has limitations, though. It measures thickness, not stiffness or pain. And skin can naturally soften in late-stage scleroderma even without treatment, as fibrosis gives way to atrophy. Clinicians have to interpret changes in the score in context rather than treating any drop as a treatment victory. Research is ongoing into better biomarkers and imaging tools that can capture fibrosis activity more precisely, but for now the skin score remains the standard.